Stryker to invest USD 400 million in CMR Surgical and sell Versius in the US

Stryker to invest USD 400 million in CMR Surgical and sell Versius in the US

12 October 2026: Stryker will invest about USD 400 million (GBP 300 million) in the British surgical robot maker CMR Surgical through preferred equity, and will become the exclusive sales agent for CMR's Versius portfolio in the United States. The agreement also gives Stryker an exclusive option to acquire all of CMR's outstanding equity in future, on the terms of the agreement.

What the money is for

CMR says the funds are meant to support future innovation and the global commercialisation of Versius. The transaction needs regulatory approvals and standard closing conditions.

CMR Surgical was founded in 2014 and is headquartered in Cambridge, England. It is a private limited company with an international shareholder base, and its current product is Versius Plus. Stryker is listed on the New York Stock Exchange as SYK and operates in MedSurg, Neurotechnology and Orthopaedics, businesses it says affect more than 150 million patients a year.

Who sells where

The split of territories is simple. In the United States Stryker becomes the exclusive sales agent for Versius, while CMR continues to lead development and commercialisation of the portfolio everywhere else.

The release says Versius is approved for use in Europe, Australia and Brazil. It does not state the product's status in the United States.

The robot Stryker is buying into

The release is aimed at hospitals and ambulatory surgery centres. CMR describes Versius as a second-generation soft-tissue surgical robot with established clinical experience worldwide. It supports a broad range of soft-tissue procedures, and its modular design is meant to give hospitals and ambulatory surgery centres flexibility across procedures, surgeon access and sites of care. The release says the design helps providers grow robotic adoption within existing operating room workflows.

Two voices and a board seat

Andy Pierce, Stryker's Group President for MedSurg and Neurotechnology, will join CMR's board of directors. He has more than 30 years of medtech leadership experience at Stryker. He said, "Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker's strengths in endoscopy."

CMR chief executive Massimiliano Colella said, "This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology." He added that Stryker's investment will give CMR additional strength to accelerate innovation, and that Stryker's scale and deep customer relationships create a significant growth opportunity in the United States. Pierce said Stryker selected CMR and the Versius portfolio because of the opportunity to help healthcare providers grow their use of robotics.

CMR's earlier funding

CMR's own news page lists earlier financing: Series A, B and C rounds, a Series D of USD 600 million, and a USD 165 million raise tied to 15,000 procedures.

The announcement was datelined Portage, Michigan, where Stryker is based, and Cambridge, England.

Company profile on TrustList: CMR Surgical

Related on TrustList:

• MassRobotics opens its healthcare robotics catalyst to cohort six
• IFR: professional service robot sales climb 24% as logistics leads
• Healthleap raises $38m in seed and Series A for hospital AI

Sources

• CMR Surgical: Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery, 12 October 2026